Finished
Hemopatch to Prevent Lymphatic Leak After Robotic Prostatectomy and Pelvic Lymph Node Dissection
NCT04185922 · Chinese University of Hong Kong · Updated 27 June 2022
- What is being tested
- Hemopatch
- For
- Prostate Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 32 people. The full rules are on the registry page.
- Where
- Hong Kong
- When
- Starts or started 27 Feb 2020, ends 10 June 2022. Registered 4 Dec 2019.
- Results
- None posted yet.
In the researchers' words
Robotic prostatectomy (RARP) is a surgery for treatment localized prostate cancer. Bilateral pelvic lymph node dissection (BPLND) will also be performed if there is an estimated risk of occult nodal metastases exceeding 5%. BPLND in general is a well-tolerated procedure. Lymphatic leak is one of the possible complications after lymph node dissection (BPLND). Lymphocele is a collection of lymphatic fluid after operation. Hemopatch is a material used during operation that may prevent lymphorrhoea. This is a randomizedcontrolled trial that aims at investigating the application of Hemopatch to raw lymphatic tissue in preventing lymphorrhoea. Patients would be divided into 2 groups: with or without the use of Hemopatch during operation. They will be followed up on day 30 to monitor the course of recovery and any complications.
Sites
- Prince of Wales HospitalHong Kong, Hong Kong
